Swiss National Bank boosted its position in shares of Cynosure Inc. (NASDAQ:CYNO) by 9.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,879 shares of the company’s stock after buying an additional 3,300 shares during the period. Swiss National Bank owned about 0.17% of Cynosure worth $1,891,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of CYNO. Meeder Asset Management Inc. purchased a new position in Cynosure during the second quarter worth $170,000. Suntrust Banks Inc. purchased a new position in Cynosure during the second quarter worth $210,000. Capital Fund Management S.A. purchased a new position in Cynosure during the second quarter worth $238,000. Investment Centers of America Inc. raised its position in Cynosure by 7.2% in the first quarter. Investment Centers of America Inc. now owns 5,980 shares of the company’s stock worth $265,000 after buying an additional 400 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Cynosure by 120.7% in the second quarter. BNP Paribas Arbitrage SA now owns 7,366 shares of the company’s stock worth $358,000 after buying an additional 4,028 shares in the last quarter. 99.51% of the stock is owned by institutional investors and hedge funds.

Cynosure Inc. (NASDAQ:CYNO) traded up 0.73% during midday trading on Thursday, reaching $54.17. 190,539 shares of the company’s stock traded hands. The company’s 50-day moving average price is $51.91 and its 200 day moving average price is $48.55. Cynosure Inc. has a 52 week low of $29.60 and a 52 week high of $55.94. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 63.96 and a beta of 1.54.

Cynosure (NASDAQ:CYNO) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.36 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.07. Cynosure had a net margin of 5.09% and a return on equity of 6.57%. The company earned $110.30 million during the quarter, compared to analyst estimates of $101.31 million. During the same quarter last year, the firm posted $0.30 EPS. The business’s revenue for the quarter was up 31.8% on a year-over-year basis. On average, equities research analysts expect that Cynosure Inc. will post $1.34 earnings per share for the current year.

A number of research firms have recently weighed in on CYNO. Zacks Investment Research lowered shares of Cynosure from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 28th. Stifel Nicolaus restated a “buy” rating and issued a $62.00 target price (up from $57.00) on shares of Cynosure in a report on Wednesday, July 27th. Maxim Group boosted their target price on shares of Cynosure from $60.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. Brean Capital set a $60.00 target price on shares of Cynosure and gave the company a “buy” rating in a report on Wednesday, September 14th. Finally, Northland Securities set a $60.00 target price on shares of Cynosure and gave the company a “buy” rating in a report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Cynosure currently has a consensus rating of “Buy” and a consensus target price of $62.00.

In other Cynosure news, Director Brian M. Barefoot sold 21,000 shares of the company’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $51.66, for a total transaction of $1,084,860.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $258,300. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Timothy W. Baker sold 2,041 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $53.19, for a total transaction of $108,560.79. Following the sale, the chief financial officer now directly owns 2,041 shares of the company’s stock, valued at $108,560.79. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

About Cynosure

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

5 Day Chart for NASDAQ:CYNO

Want to see what other hedge funds are holding CYNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cynosure Inc. (NASDAQ:CYNO).

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.